This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Power calculations to determine the sample size were not reported. Of the 390 consecutive patients identified by four independent psychologists at the study hospital from 1994 to 1996, 110 were eligible. Ten patients were diverted to another study and 5 patients dropped out before randomisation. Thus, the final study sample comprised 95 patients for allocation to the study groups. However, 21 patients (12 in the combined treatment group and 9 in the clomipramine alone group) were excluded from the analysis. A sample of 74 patients was therefore enrolled, of which 35 were in the combined treatment group and 39 in the clomipramine alone group. The patients in the combined treatment group were aged 36 (+/-9.5) years and 66% were women. The patients in the clomipramine alone group were aged 36.7 (+/-10.4) years and 56% were women.
Study design
This was a randomised controlled trial, which was carried out in a single centre. Randomisation was carried out after stratification by presence of personal disorders, past major depressive syndrome, and gender. The patients were followed for 10 weeks. Twelve patients in the combined treatment group and 9 in the clomipramine alone group were lost to follow-up. This was due to patients not returning for treatment, patients dropping out against medical advice, and the discovery of exclusion criteria not detected at the study entry. All outcome raters were independent, and the nurse and clinical staff did not participate in the outcome assessment. The psychologist who made the assessment was blinded to the patient allocation. However, the authors stated that there was no blinding when it came to the measurement of severity of depression and the Health-Sickness Rating Scale (HSRS) score, because the patients were receiving intensive care.
Analysis of effectiveness
The basis for the analysis of the clinical study was treatment completers only, but an intention to treat analysis was also conducted. The primary health outcomes used in the effectiveness analysis were the severity of depression (HDRS) at intake and at 10 weeks, the Global Assessment Scale (GAS) score at intake and discharge, the number of days of hospitalisation and sick leave, and the actual number of hospitalisation episodes. The study groups were comparable at baseline in terms of the demographics and disease conditions. The authors also stated that patients lost to follow-up were comparable with those who remained in the study.
Effectiveness results
At baseline, the HDRS score was 24.3 (+/-3.2) in the combined treatment group and 24 (+/-2.9) in the clomipramine alone group. The corresponding scores at 10 weeks were 8.9 (+/-7) (combined treatment) and 9.7 (+/-7.3) (clomipramine alone), respectively.
At baseline, the GAS score was 43.3 (+/-3.7) in the combined treatment group and 43.1 (+/-4.1) in the clomipramine alone group. The corresponding scores at discharge were 62.8 (+/-6.8) (combined treatment) and 58.3 (+/-7.2) (clomipramine alone), respectively, (p=0.006).
The number of days of hospitalisation was 1.1 (+/-2.2) in the combined treatment group and 3.2 (+/-5.9) in the clomipramine alone group, (p=0.04).
The duration of sick leave was 46.1 (+/-37.1) days in the combined treatment group and 57.9 (+/-38.6) days in the clomipramine alone group, (not significant).
The actual number of hospitalisation episodes was 2 (6%) in the combined treatment group and 9 (23%) in the clomipramine alone group, (p=0.05).
The study results were unchanged when an intention to treat analysis was performed.
Clinical conclusions
The effectiveness analysis showed that the combined treatment was more effective than clomipramine alone in improving the patients' health condition and in reducing hospitalisation and sick leave.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic study. A costconsequences analysis was therefore carried out.
Direct costs
The cost/resource boundary adopted in the analysis of the direct costs was not reported. The health service costs included in the economic evaluation were nurse visits, psychotherapy session, psychoeducation, psychiatric examination (by resident or attendant psychiatrist), clinical supervision, psychotherapy supervision, days of hospitalisation and additional outpatient treatment. The authors assumed that some specific expenses, such as clomipramine administration, equipment and assessment, were similar for both treatment groups. Discounting was not relevant since the time horizon of the study was 10 weeks. The unit costs were not reported separately from the quantities of resources used. Resource consumption was estimated using data collectively gathered from the same sample of patients as that used in the effectiveness trial from 1994 to 1996. The source of the unit cost data was not explicitly reported. No price year was given.
Statistical analysis of costs
The costs were treated descriptively.
Indirect Costs
The indirect costs were included. Thus, it appears that a societal perspective has been adopted in the analysis. The unit cost of a workday lost and the number of workdays lost were reported. The costs were estimated from the public health section of the Geneva Bureau of Statistics. Days of sick leave equalled the days spent at treatment. No price year was reported. No discounting was applied since the costs were incurred over a short time period.
Currency
US dollars ($). The costs were converted from Swiss francs (SFr) into American dollars. The conversion rate was SFr 1.40 = $1.
Sensitivity analysis
Sensitivity analyses were not conducted.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total direct costs were $2,976 (+/-835) in the combined treatment group and $3,441 (+/-966) in the clomipramine group.
The total indirect costs were $7,211 (+/-5,804) in the combined treatment group and $9,057 (+/-6,038) in the clomipramine group.
The total costs per patient were $10,187 (+/-2,859) in the combined treatment group and $12,498 (+/-3,057) in the clomipramine group.
